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Objective: The objective of this study was to compare the underestimation rate of
invasive carcinoma in cases with ductal carcinoma in situ (DCIS) at percutaneous
ultrasound-guided core biopsies of breast lesions between 14-gauge automated core-
needle biopsy (ACNB) and 8- or 11-gauge vacuum-assisted biopsy (VAB), and to
determine the relationship between the lesion type (mass or microcalcification on
radiological findings) and the DCIS underestimation rate.
Methods: We retrospectively reviewed imaging-guided biopsies of breast lesions
performed from February 2003 to August 2008. 194 lesions were diagnosed as DCIS at
ultrasound-guided core biopsy: 138 lesions in 132 patients by 14-gauge ACNB, and 56
lesions in 56 patients by 8- or 11-gauge VAB. The histological results of the core biopsy
samples were correlated with surgical specimens. The clinical and radiological findings
were also reviewed. The histological DCIS underestimation rates were compared
between the two groups and were analysed for differences according to the clinical
and radiological characteristics of the lesions.
Results: The DCIS underestimation rate was 47.8% (66/138) for 14-gauge ACNB and
16.1% (9/56) for VAB (p,0.001). According to the lesion type on sonography, DCIS
underestimation was 43.4% (63/145) in masses (47.6% using ACNB and 15.8% using
VAB; p50.012) and 24.5% (12/49) in microcalcifications (50.0% using ACNB and 16.2%
using VAB; p50.047).
Conclusion: The underestimation rate of invasive carcinoma in cases with DCIS at
ultrasound-guided core biopsies was significantly higher for ACNB than for VAB.
Furthermore, this difference does not change according to the lesion type on
ultrasound. Therefore, ultrasound-guided VAB can be a useful method for the
diagnosis of DCIS lesions presented as either mass or microcalcification.
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Ductal carcinoma in situ (DCIS) is mostly presented as
microcalcification on radiography. Therefore, previous
reports regarding the accuracy of core biopsy in DCIS
have mainly focused on stereotactic (ST) guidance
[1–4]. With the development and introduction of high-
resolution ultrasound, several reports have studied
various applications of ultrasound on the core biopsy
for breast lesions, including ultrasound-guided core
biopsy for microcalcification [5–9] and ultrasound-
guided vacuum-assisted removal [10]. Ultrasound gui-
dance has several advantages over ST guidance: a lack
of ionising radiation, use of non-dedicated equipment,
real-time needle visualisation, multidirectional sampling,
lower cost [8, 11] and less patient discomfort [8, 11–13].
For these reasons, ultrasound-guided core biopsy may be
preferable in lesions that are amenable to core biopsy
with both ST and ultrasound guidance.
One critical issue in percutaneous biopsy for diag-
nosis of DCIS may be DCIS underestimation, which
means the underestimation of invasive cancer in cases
where the core biopsy shows DCIS [1]. As under-
estimated DCIS at the core biopsy is upgraded to
invasive carcinoma at surgery, axillary node dissection
at a later date and thus a two-stage therapeutic surgical
procedure can be resulted in [1]. The DCIS under-
estimation rate in ST-guided core biopsy is generally
10–36% with a large number of cases. Among them,
11-gauge vacuum-assisted biopsy (VAB) is well known
to show a significantly lower DCIS underestimation
rate than 14-gauge automated core-needle biopsy
(ACNB) under ST-guidance [1, 14–16]. However,
studies with ultrasound-guided core biopsy have not
found significant differences in DCIS underestimation
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between ACNB and VAB [17–18]. Moreover, previous
studies using ultrasound guidance included only a small
number of cases, and it is not well establishedwhether the
biopsy device (ACNB or VAB) and lesion type (micro-
calcification or mass) would affect the underestimation
rate under ultrasound guidance.
The purpose of this study was to compare the under-
estimation rate of invasive carcinoma in cases with DCIS at
ultrasound-guided core biopsies between 14-gauge ACNB
and VAB, and to determine the relationship between lesion
types (mass or microcalcification on radiological findings)
and the DCIS underestimation rate.
Methods and materials
This retrospective study was conducted with institu-
tional review board approval and patient informed
consent was waived.
Study population
From a retrospective review of the radiological data-
base of our institution from February 2003 to August 2008,
we found 207 breast lesions that were diagnosed as DCIS
from 6012 imaging-guided biopsies, comprising 5061
ultrasound-guided ACNB, 921 ultrasound-guided VAB
and 30 ST-guided VAB (Figure 1). Among 207 DCIS
lesions, 3 lesions with ST-guided VAB were excluded. No
lesion was diagnosed as DCIS with MR-guided biopsy
during the study period. Therefore, a total of 204
consecutive lesions were diagnosed as DCIS at ultra-
sound-guided core biopsies (138 lesions in 132 patients
using 14-gauge ACNB and 66 lesions in 66 patients using
8- or 11-gauge VAB). Excluding 10 patients who were lost
during the follow-up, 188 patients with 194 DCIS lesions
(138 lesions in 132 patients using ACNB and 56 lesions in
56 patients using VAB) who underwent surgical excision
at our institution made up our study population
(mastectomy in 145 patients and conserving surgery in
43 patients). Of the 132 patients in the ACNB group, 126
patients had one lesion biopsied while 6 patients had
biopsies of two separate lesions. All 56 patients in the VAB
group underwent biopsy for one lesion.
Biopsy procedures
The breast biopsy device that was used depended
primarily on the standard protocol of our institution
(Figure 2). At our institution, ultrasound was subse-
quently performed for a mammographically detected
lesion, which was indicated for biopsy, classified as
Breast Imaging Reporting and Data System (BI-RADS)
final assessment category 4 or 5. When the lesion on
mammography was not visible in ultrasound or not
correlated with ultrasound finding, ST-guided VAB was
performed. If any mass or microcalcification (hyper-
echoic foci that was not related to Cooper’s ligament)
was detected on ultrasound at the location that may be
correlated with the location of mammography, mammo-
graphy was performed with the skin marker attached to
the site at which the mass or microcalcification was
seen on ultrasound. If the ultrasound-detected mass or
microcalcification was correlated with the mammogra-
phy-detected lesion, ultrasound-guided core biopsy was
subsequently performed for this lesion. Selection of
biopsy device among ACNB or VAB under ultrasound
guidance was dependent on the lesion factors and
clinical factors as follows. Generally, ultrasound-guided
14-gauge ACNB is initially performed to biopsy sono-
graphically visible breast masses regardless of the
palpability of the lesion [12, 19–20]. However, VAB was
preferred for lesions in which there were potential
benefits from using the device [8, 21], including lesions
with heterogeneous characteristics, intraductal lesions
and microcalcification visible in ultrasound. For micro-
calcification, even if presented without an associated
mass, ultrasound-guided VAB was preferred over ST-
guided whenever the lesion was sonographically visible
and correlated with mammographic abnormality, con-
sidering the aforementioned advantages of ultrasound-
guided over ST-guided. Although ACNB was mainly
performed for mass lesions, if the patient or referring
physician preferred removal of the lesion with concur-
rent histological diagnosis, mass lesions were also
indications for VAB. However, a mass lesion classified
as BI-RADS final assessment category 4c or 5 was not an
indication of VAB for an aim of removal of the lesion.
Although this protocol was present, the physician’s and
patient’s preferences also affected the decision.
All biopsies were performed using the freehand
technique, guided by high-resolution sonography units
with a 12-MHz linear array transducer (ATL HDI
5000; Philips Advanced Technology Laboratories,
Bothell, WA) with the patient in the supine or oblique
supine position. Of the 194 DCIS lesions, ultrasound-
guided ACNB was performed in 138 breast lesions using
automated guns (Pro-Mag 2.2; Manan Medical Products,
Figure 1. Flow chart of the study.
DCIS, ductal carcinoma in situ; ST,
stereotactic.
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Northbrook, IL) and 14-gauge Tru-cut needles with a
22-mm throw. VAB was performed in 56 lesions using 8-
or 11-gauge needles (Mammotome; Ethicon-Endosurgery,
Cincinnati, OH). When VAB was used, an 8-gauge needle
was selected for a lesion larger than 1.5 cm diameter and
11-gauge was for a lesion of 1.5 cm or smaller diameter,
but each radiologist’s preference was also considered.
Following our standard protocol, four to six core samples
per lesion were obtained using ACNB by one of our four
board-certificated radiologists. When VAB was used, the
procedure was usually performed at the discretion of each
radiologist, depending on the size of the lesion as seen on
sonography and on the aim of VAB. Whenever a lesion
that contained microcalcifications was biopsied, a speci-
men radiograph was obtained to document the presence
of calcifications. The maximum diameter of the lesion was
measured by sonography before the biopsy procedure
and used as the parameter indicating the size of the lesion
throughout this study.
Prior to core biopsy, the lesions were prospectively
characterised according to the guidelines of the American
College of Radiology BI-RADS final assessment categories
both on mammography and sonography by the radiolo-
gist who performed the biopsy [19]. The aim of the biopsy
(either diagnostic or removal) in the case of a VAB lesion
was recorded. Post-biopsy complication (e.g. bleeding,
skin laceration) was also recorded.
Imaging and histological evaluation
For this study, all imaging studies were retrospectively
reviewed by MJK (8 years of experience with breast
imaging), who was blinded to the surgical pathological
diagnosis. The images were reviewed on a picture ar-
chiving and communications system (Centricity 2.0; GE
Healthcare, Waukesha, WI).
Based on the results of the retrospective review, the
characteristics of the lesions on mammography and
sonography were described in terms of the lesion type
and size. Aside from 10 lesions in the ACNB group and 1
lesion in the VAB group, mammography was available
for all lesions.
On mammography, the lesion type was classified into
one of two groups according to the characteristics of the
lesion: mass or microcalcification. Any mass, architec-
tural distortion or asymmetry seen on mammography,
with or without calcifications, was classified as a mass. If
microcalcification was presented without an associated
mass, architectural distortion or asymmetric density on
mammography, it was classified as a microcalcification.
On sonography, all lesions were also classified as either a
mass or microcalcification. Any mass seen on sonogra-
phy, regardless of the presence of microcalcifications,
was classified as a mass. If microcalcification was present
without an associated mass, the lesion was classified as a
microcalcification.
The histological results of the core biopsy samples
were correlated with the pathological report on surgical
specimens. Histological DCIS underestimation of inva-
sive carcinoma was defined as DCIS diagnosed via core
biopsy that was later upgraded to invasive carcinoma
at surgery. DCIS with microinvasion was considered as
invasive carcinoma. The DCIS underestimation rate was
defined as the percentage of the number of invasive
carcinomas upgraded at subsequent surgery divided by
the number of total lesions or patients diagnosed as DCIS
at core biopsy.
Outcome analysis
Statistical comparisons were performed between the
ACNB group and the VAB group in terms of the clinical
and imaging characteristics: symptoms, patient’s age,
lesion size, final assessment of BI-RADS category and
lesion type on imaging study. In cases of VAB, clinical
and imaging characteristics of the lesion and the mean
number of core samples were compared according
to the diameter of the biopsy needle used (8-gauge vs
11-gauge).
Figure 2. Biopsy protocol of breast
lesion for selection of the devices at
our institution. ACNB, automated
core-needle biopsy; BI-RADS, Breast
Imaging Reporting and Data System;
ST, stereotactic.
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The DCIS underestimation rates of the two biopsy
methods were compared per lesion and per patient. In
cases of VAB, the DCIS underestimation rate for 8-
and 11-gauge needle was obtained. The rates were also
analysed with respect to the type of the lesion on
sonography or mammography and the final assessment
of the BI-RADS category.
Student’s t-test was performed to compare the patient
ages, lesion sizes and the numbers of samples obtained
per lesion between the two biopsy groups. The x2 test or
Fisher’s exact test was performed to compare sono-
graphic and mammographic lesion types with DCIS
underestimation rates. For all analyses, the results were
considered statistically significant if the p-value was
,0.05. For statistical analysis, we used a computerised
statistics program (Med-Calc for Windows, v. 8.0.0.1;
MedCalc Software, Mariakerke, Belgium).
Results
The data in Table 1 demonstrate the clinical and
imaging variables of the lesions in the ACNB and VAB
groups. There were associated symptoms present in 68
cases (34.7%): a palpable mass in 57 cases, bloody nipple
discharge in 10 cases and both in 1 ACNB case. The lesion
size measured by sonogram ranged from 4 to over
100 mm (mean 18.5mm; median 15.0mm). There was
no significant difference in the mean lesion size between
the two biopsy groups (p50.28). The distribution of BI-
RADS category was not different between the two groups
(p50.06). The percentage of microcalcification lesions
on sonography and mammography compared with the
percentage of mass lesions was significantly higher in the
VAB group than in the ACNB group (p,0.001). The mean
number of core samples obtainedwas 5.01 (range 3–17) for
14-gauge ACNB and 11.8 (range, 5–28) for 8- and 11-gauge
VAB (p,0.0001).
An 8-gauge needle was used in 16 lesions and an
11-gauge needle was used in 40 lesions, according to the
size of the lesion. The lesion size had a mean of 20.5mm
(range 15–33mm, median 18.5mm) in the 8-gauge group
and a mean of 11.9mm (range 5–17mm, median
12.0mm) in the 11-gauge group (p50.013). The mean
number of core samples was 12.9 (range 7–28) for 8-
gauge VAB and 11.3 (range 5–23) for 11-gauge VAB
(p50.24). There was no statistically significant difference
between the cases with 8-gauge and those with 11-gauge
regarding the lesion type on mammography (p50.23),
that on sonography (p50.13), the presence of symptoms
(p50.20) and the distribution of BI-RADS category
(p50.24). Among 56 VAB cases, nine lesions (four with
8-gauge and five with 11-gauge) were performed for
removal of mass lesion.
Histological ductal carcinoma in situ
underestimation rate
Of the 194 lesions in 188 patients that were given
the pathological diagnosis of DCIS in core biopsy, the
final pathological results of surgical resection showed
an invasive component in 38.7% of the cases (75/194).
DCIS underestimation occurred in 47.8% (66/138) of
the ACNB cases and in 16.1% (9/56) of the VAB cases
(p,0.001; Table 2). Among the six patients who had two
separate lesions, five had the same diagnosis at surgery
for the two lesions (DCIS for two patients and IDC for
Table 1. Patient and lesion variables in lesions diagnosed as DCIS by 14-gauge ACNB and 8- and 11-gauge VAB
Variable ACNB (n5138) VAB (n556) Total (n5194) p-value
Patient age (years) 0.89
Mean¡SD 47.8¡10.2 48.0¡10.5 47.8
Range 24–88 25–70 24–88
Associated symptomsa 58 10 68b
0.001Lesion size (mm)c
Mean¡SD 18.9¡13.2 15.5¡7.81 18.5¡12.7 0.28
Range 4–100 5–33 4–100
BI-RADS category 0.06
3 1 (0.7) 2 (3.5)
4a 39 (28.3) 16 (28.6)
4b 12 (8.7) 9 (16.1)
4c 31 (22.5) 17 (30.4)
5 55 (39.8) 12 (21.4)
Lesion type on mammography 128d 55d ,0.001
No abnormality 20 (15.6) 6 (10.9) 26
Mass 58 (45.3) 7 (12.7) 65
Microcalcification 50 (39.1) 42 (76.4) 92
Lesion type on sonography ,0.001
Mass 126 (91.3) 19 (33.9) 145
Microcalcification 12 (8.7) 37 (66.1) 49
ACNB, automated core-needle biopsy; BI-RADS, Breast Imaging Reporting and Data System; DCIS, ductal carcinoma in situ; SD,
standard deviation; VAB, vacuum-assisted biopsy.
The numbers in parentheses are percentages.
aAssociated symptoms indicate palpable breast mass or bloody discharge.
bOne patient in ACNB had both symptoms; palpable mass and bloody discharge.
cSize of lesion was measured using sonography by radiologist who performed biopsy.
dNumber of lesions by mammography was available.
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three patients), while only one patient had a different
diagnosis for each lesion (DCIS for one and IDC for
another). We considered the last patient to be under-
estimated. Thus, DCIS underestimations per patient
were 39.9% (75/188), representing 48.5% (64/132) for
ACNB, and 16.1% (9/56) for VAB.
According to the diameter of the biopsy needle used in
the VAB lesions, the DCIS underestimation rate was
18.8% (3/16) for lesions diagnosed with 8-gauge VAB
and 15% (6/40) for lesions diagnosed with 11-gauge
VAB. Because there was not a significant difference
between the underestimation rates for the 8- and 11-
gauge vacuum-assisted probes (p50.95), data for the two
probes were combined throughout the study.
According to the types of the lesions by sonography,
the DCIS underestimation rate was 43.4% (63/145) for
mass lesions and 24.5% (12/49) for microcalcification
lesions (p50.029). For masses, the DCIS underestimation
rate was 47.6% (60/126) with ACNB and 15.8% (3/19)
with VAB, and the difference between the two groups
was statistically significant (p50.012). For microcalcifica-
tions, the rate was 50.0% (6/12) with ACNB and 16.2%
(6/37) with VAB, and this difference was also significant
(p50.047).
Concerning the types of the lesions as diagnosed by
mammography, 53.8% (14/26) of lesions showed no
abnormality in mammography, and 41.5% (27/65) of
masses and 32.6% (30/92) of microcalcifications were
underestimated as DCIS (p50.12). In the differences of
DCIS underestimation between the two biopsy device
groups, there was statistical significance in the cases
involving microcalcifications (p,0.001) on mammography.
No post-biopsy complication was noted in either
biopsy device group.
Discussion
In previous reports, the diagnosis of DCIS using
percutaneous imaging-guided core biopsies of breast
lesions underestimated the presence of invasive breast
cancer in 15–36% of the cases when using ACNB and in
10–31% of cases when using VAB under ST guidance
(Table 3). Under ultrasound guidance, the DCIS under-
estimation rates were 39–67% for 14-gauge ACNB and
17–41% for VAB [3, 17, 20–23]. Our ultrasound-guided
ACNB DCIS underestimation rate (47.8%) was compa-
tible with the ultrasound-guided ACNB underestimation
rates in previous reports, but was higher than the ST-
guided rates. For VAB, the DCIS underestimation rate
(16.1%) in our study was slightly lower than the rates
with both ST and ultrasound guidance in previous
reports. Finally, the differences of DCIS underestima-
tion between the two biopsy methods (p,0.001) showed
statistical significance in our study. There are several
possible reasons for this observed difference. First,
ultrasound guidance was used in our study. In previous
studies, a higher DCIS underestimation was seen in
ultrasound-guided ACNB than in ST-guided ACNB [1–2,
5, 17, 23–24]. This is consistent with the higher under-
estimation of DCIS lesions that presented as a mass
lesion on radiography [1, 3, 17], considering that
ultrasound-guided ACNB was applied to sonographi-
cally visible mass lesions in our study. Second, the
amount of tissue samples obtained in VAB cases may
have been larger than in previous studies. VAB cases in
which a larger-diameter needle was used (8-gauge) were
included in our study. Previous reports only included
11-gauge needles, and the larger needles in our report
could allow for the acquisition of more tissue, which may
result in a lower DCIS underestimation rate. Despite this
theoretical advantage of larger needles, the underestima-
tion rates of 8-gauge probes and 11-gauge probes were
similar in our study (p50.95), even though the mean
diameter of the lesions was larger in the 8-gauge cases
(p50.013). Therefore, the possible effect of the 8-gauge
probe on the DCIS underestimation should be addressed
in a future study.
Recently, Cho et al [17] compared the outcomes of 14-
gauge ACNB and 11-gauge VAB used in ultrasound-
guided core biopsies of breast lesions, and found DCIS
underestimation of 50% (5/10) for 14-gauge ACNB and
41% (7/17) for 11-gauge VAB, but the difference was not
statistically significant. A lower DCIS underestimation
rate of VAB in our study (16.5%) was possibly due to
a larger number of cases, the cases of lesion removal
and/or the cases in which the larger 8-gauge biopsy
needle was used. Moreover, for the biopsies performed
using 11-gauge VAB, the mean number of core samples
reported in Cho et al’s study was 10.2 (range 6–30) [17],
while the mean number of core samples in our study was
11.3 (range 5–23). Considering the larger mean size of
Table 2. The DCIS underestimation rates for the two biopsy devices according to the type of lesion on sonography
Variable ACNB VAB Total p-value
Per lesion 66/138 (47.8) 9/56 (16.1) 75/194 (38.7) ,0.001
Lesion type on sonography
Mass 60/126 (47.6) 3/19 (15.8) 63/145 (43.4) 0.012
Microcalcification 6/12 (50.0) 6/37 (16.2) 12/49 (24.5) 0.047
Lesion type on mammography
No abnormality 12/20 (60.0) 2/6 (33.3) 14/26 (53.8) 0.37
Mass 26/58 (44.8) 1/7 (14.3) 27/65 (41.5) 0.22
Microcalcification 24/50 (48.0) 6/42 (14.3) 30/92 (32.6) ,0.001
Per patient 64/132 (48.5) 9/56 (16.1) 75/188 (39.9) ,0.001
Lesion type on sonography
Mass 58/120 (48.3) 3/19 (15.8) 61/139 (43.9) 0.011
Microcalcification 6/12 (50.0) 6/37 (16.2) 12/49 (24.5) 0.047
ACNB, automated core-needle biopsy; VAB, vacuum-assisted biopsy.
The numbers in the parentheses are percentages.
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lesions in Cho et al’s study (13.0mm; range 3–55mm) for
VAB compared with the lesions of our study (mean
11.9mm; range 5–20mm in 11-gauge VAB), the acquisi-
tion of a larger number of core samples would be better
when DCIS is suspected. To our knowledge, our study is
the first report that shows a significant difference in the
DCIS underestimation rates of ACNB and VAB when
using ultrasound guidance.
In our study, a higher DCIS underestimation rate was
observed in mass lesions (43.4%) than in microcalcifica-
tions (24.5%), which is consistent with the results of
previous reports [1, 3, 21]. To determine the relationship
between the lesion type and the DCIS underestimation
rate, we compared the DCIS underestimation rates of
ACNB and VAB in masses and microcalcifications
separately. The VAB group had lower DCIS under-
estimation rates than those of the ACNB group in both
masses and microcalcifications. These results show that
VAB has an advantage over ACNB in terms of DCIS
underestimation with ultrasound guidance, regardless of
the lesion type. However, we do not claim that VAB is
always the superior choice for mass lesions detected on
radiography if the core biopsy is intended for diagnostic
purposes and if the lesion has the appropriate size for
ACNB.
Indeed, as shown in Figure 2, following standard
protocol in our institution, ACNB is a preferred choice
for mass lesion with diagnostic purpose, although
ultrasound VAB shows better diagnostic accuracy. That
is because ACNB itself also shows a high diagnostic
accuracy of about 96% [23, 25] and costs less than VAB.
However, ultrasound VAB was preferred to ultrasound
ACNB in some limited indications that required a larger
sampling (e.g. in microcalcification visible on ultrasound,
heterogeneous lesion and intraductal lesion). In pre-
vious studies, VAB showed better accuracy for retrieval
of microcalcification than ACNB. Furthermore, when
microcalcification is visible on ultrasound, ultrasound
guidance has several advantages over ST guidance, such
as less patient discomfort from position, a lack of
ionising radiation, real-time needle visualisation, multi-
directional sampling and lower cost [8, 11–13]. VAB is
preferred for heterogeneous lesions on imaging, such as
DCIS (suggesting the possibility of heterogeneous
pathology [26]), and for intraductal lesions (suggesting
the possibility of papillary lesions [27]), as the risk of
underestimation in these lesions is considered to be high
and large tissue sampling is required. Despite the
standard protocol, however, ultrasound ACNB was
performed on some cases for reasons such as the
patient’s economic burden. Although we described some
indications for which VAB would be helpful, further
study is needed to establish a standard set of indications
for VAB.
It has been thought that histological DCIS under-
estimation is a problem often encountered when micro-
calcification is biopsied under ultrasound guidance
[17, 28–29]. Despite the high percentage of microcalcifica-
tion lesions in the VAB group, we found a lower DCIS
underestimation rate in this group than that in the ACNB
group. This finding was probably due to better sampling
of lesions with VAB. In ACNB, if air is introduced into
the biopsy cavity after the pass of the biopsy needle, the
gas in the biopsy track can have a focal echogenic
appearance and/or cause shadowing, thereby mimick-
ing or obscuring the original echogenic target. VAB
might help to solve this problem because it can suction
air and/or blood away from the biopsy cavity during the
procedure [13, 30]. Unlike ACNB, the probe is positioned
posterior to the lesion so that it does not overshadow
(and thereby obscure) the lesion during ultrasound-
guided VAB. Consequently, the progress of lesion
removal can be monitored in real time in VAB.
Furthermore, repositioning of the probe aperture, which
Table 3. Reference review of DCIS underestimation rates: comparison of biopsy devices
Reference
Publi-
cation
year Guidance Devices
No. of
biopsied
lesions
No. of
included
DCIS
lesions at
biopsy
Rate of
DCIS in
biopsied
lesions
No. of DCIS
underesti-
mation
lesions
DCIS
underes-
timation
rates
Statistical
significance
Won et al [2] 1999 ST 14G ACNB 154 20 12.9% 7 35% NS
11G VAB 236 20 8.4% 3 15%
Darling et al [3] 2000 ST and
ultrasound
14G ACNB 3873 67 7.5% 14 21% NSa p50.01
14G VAB 47 8 17%
11G VAB 175 18 10%
Schoonjans and Brem [34] 2001 Ultrasound 14G ACNB 424 9 3.7% 5 55.5% NA
Jackman et al [1] 2001 ST 14G ACNB 13640 373 9.7% 76 20.4% p,0.001
14, 11G VAB 953 107 11.2%
Crowe et al [35] 2003 Ultrasound 14G ACNB 832 33 4.0% 17 51.5% NA
Cho et al [17] 2005 Ultrasound 14G ACNB 562 10 1.8% 5 50% NS
11G VAB 417 17 4.0% 7 41%
Sauer et al [36] 2005 Ultrasound 14G ACNB 962 18 18.7% 11 61.1% NA
Crystal et al [37] 2005 Ultrasound 14G ACNB 715 6 0.8% 4 66.7% NA
Londero et al [5] 2007 Ultrasound 14G ACNB 2423 65 2.7% 27 41.5% NA
Cassano et al [20] 2007 Ultrasound 11G VAB 414 12 3.0% 2 16.7% NA
Youk et al [23] 2008 Ultrasound 14G ACNB 4359 126 2.9% 36 39% NA
Current study 2012 Ultrasound 14G ACNB 5061 138 2.7% 66 47.8% p,0.001
8G,11G VAB 921 56 7.2% 9 16.1%
ACNB, automated core-needle biopsy; DCIS, ductal carcinoma in situ; G, gauge of needle; NA, not applicable; NS, not significant;
ST, stereotactic guided; VAB, vacuum-assisted biopsy.
aSignificant between ACNB and 11G VAB but not between ACNB and 14G VAB.
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can affect the accuracy of the biopsy results, is not
needed in VAB [13, 31]. Finally, one can extract more
tissue when using VAB. Therefore, ultrasound VAB
would be a better choice for mass lesions with hetero-
geneous characteristics or intraductal location, or micro-
calfication lesions visible on ultrasound, especially for
the cases in which ST-guided biopsy is not available (i.e.
when the patient is unable to undergo proper positioning
for ST-guided biopsy or if the location of the targeted
microcalcification does not permit stereotactic localisa-
tion), ultrasound-guided core biopsy may be an effective
alternative method, and ultrasound-guided VAB appears
to be the superior choice over ACNB.
Our study had several limitations. First, because this
was a retrospective study, some degree of selection bias
for the use of biopsy devices could not be avoided. To
overcome possible selection bias, we compared the DCIS
underestimation between two biopsy device groups by
lesion type. Second, the high percentage of mass lesions
(145 masses and 49 microcalcifications on sonography,
and 65 masses and 92 microcalcaifications on mammo-
graphy) of our study population does not reflect the
pattern of previous literature [32–33]. Indeed, we did not
analyse the exact percentage of mass lesions out of all
biopsied lesions during the study period. Considering
that the percentage of lesion type may have an effect on
the results of DCIS underestimation, we compared the
DCIS underestimation rates of the two groups according
to the lesion type to minimise the effects of lesion type
on the results. Third, a comparison between ACNB and
each VAB probe (8- vs 11-gauge) was not performed,
because our study was focused on a comparison of the
DCIS underestimation rate between ACNB and VAB.
Indeed, the cases with 8-gauge and those with 11-gauge
had similar clinical and imaging characteristics, and a
decision about needle size was largely dependent on the
lesion size in this study. Moreover, DCIS underestima-
tions of both needles were not significantly different.
Another possible limitation can be the small number of
mass lesions with VAB to generalise our results. Finally,
data analysis was performed only for the DCIS under-
estimation rate, not for other outcomes, such as rebiopsy
rate or false-negative rate.
In conclusion, the DCIS underestimation rate of ultra-
sound-guided core biopsies was significantly higher for
ACNB relative to VAB. This difference did not change
according to the lesion type on sonography. Therefore,
ultrasound-guided VAB can be a useful method in
the diagnosis of DCIS lesions presented as either mass
or microcalcification. However, when deciding which
biopsy method is the most effective, many factors should
be taken into consideration, including cost, time required
for the biopsy, potential complications and the prefer-
ences of the clinician and the patient.
References
1. Jackman RJ, Burbank F, Parker SH, Evans WP 3rd, Lechner
MC, Richardson TR, et al. Stereotactic breast biopsy of
nonpalpable lesions: determinants of ductal carcinoma in
situ underestimation rates. Radiology 2001;218:497–502.
2. Won B, Reynolds HE, Lazaridis CL, Jackson VP. Stereotactic
biopsy of ductal carcinoma in situ of the breast using an 11-
gauge vacuum-assisted device: persistent underestimation
of disease. AJR Am J Roentgenol 1999;173:227–9.
3. Darling M, Smith D, Lester S, Kaelin C, Selland D, Denison C,
et al. Atypical ductal hyperplasia and ductal carcinoma in situ
as revealed by large-core needle breast biopsy: results of
surgical excision. AJR Am J Roentgenol 2000;175:1341–6.
4. Jackman R, Nowels K, Rodriguez-Soto J, Marzoni FJ,
Finkelstein S, Shepard M. Stereotactic, automated, large-core
needle biopsy of nonpalpable breast lesions: false-negative
and histologic underestimation rates after long-term follow-
up. Radiology 1999;210:799–805.
5. Londero V, Zuiani C, Furlan A, Nori J, Bazzocchi M. Role of
ultrasound and sonographically guided core biopsy in the
diagnostic evaluation of ductal carcinoma in situ (DCIS) of
the breast. Radio Med 2007;112:863–76.
6. Moon W, Im J-G, Noh D. US of mammographically detected
clustered microcalcifications. Radiology 2000;217:849–54.
7. Schoonjans J, Rache R. Sonographic appearance of ductal
carcinoma in situ diagnosed with ultrasonographically guided
large core needle biopsy: correlation with mammographic and
pathologic findings. J Ultrasound Med 2000;19:449–57.
8. Soo M, Baker J, Rosen E. Sonographic detection and sono-
graphically guided biopsy of breast microcalcifications. AJR
Am J Roentgenol 2003;180:941–8.
9. Yang W, Suen M, Ahuja A, Metreweli C. In vivo demonstra-
tion of microcalcification in breast cancer using high
resolution ultrasound. Br J Radiol 1997;70:685–90.
10. Kim M, Kim EK, Lee JY, Youk JH, Park BW, Kim SI, et al.
Breast lesions with imaging-histologic discordance during
US-guided 14G automated core biopsy: can the directional
vacuum-assisted removal replace the surgical excision?
Initial findings. Eur Radiol 2007;17:2376–83.
11. Fajardo L, Pisano E, Caudry D, Gatsonis C, BergW, Connolly
J. Stereotactic and sonographic large-core biopsy of non-
palpable breast lesions: results of the Radiologic Diagnostic
Oncology Group V study. Acad Radiol 2004;11:293–308.
12. Liberman L, Feng T, Dershaw D, Morris E, Abramson A.
Ultrasound-guided core breast biopsy: use and cost-effec-
tiveness. Radiology 1998;208:717–23.
13. Youk JH, Kim E-K, Kim MJK, Lee JY, Oh KK. Missed breast
cancers at US-guided core needle biopsy: how to reduce
them. Radiographics 2007;27:79–94.
14. Burbank F. Stereotactic breast biopsy of atypical ductal
hyperplasia and ductal carcinoma in situ lesions: improved
accuracy with directional, vacuum-assisted biopsy. Radiology
1997;202:843–7.
15. Jackman RJ, Burbank F, Parker SH, Evans WP 3rd, Lechner
MC, Richardson TR, et al. Atypical ductal hyperplasia
diagnosed at stereotactic breast biopsy: improved reliability
with 14-gauge, directional, vacuum-assisted biopsy. Radiology
1997;204:485–8.
16. Philpotts L, Lee C, Horvath L, Lange R, Carter D, Tocino I.
Underestimation of breast cancer with 11-gauge vacuum
suction biopsy. AJR Am J Roentgenol 2000;175:1047–50.
17. Cho N, Moon WK, Cha JH, Kim SM, Kim SJ, Lee SH, et al.
Sonographically guided core biopsy of the breast: comparison
of 14-gauge automated gun and 11-gauge directional vacuum-
assisted biopsy methods. Korean J Radiol 2005;6:102–9.
18. Philpotts LE, Hooley RJ, Lee CH. Comparison of automated
versus vacuum-assisted biopsy methods for sonographically
guided core biopsy of the breast. AJR Am J Roentgenol 2003;
180:347–51.
19. American College of Radiology. Breast imaging reporting
and data system (BI-RADS). Reston, VA: American College
of Radiology; 2003.
20. Cassano E, Urban LABD, Pizzamiglio M, Abbate F,
Maisonneuve P, Renne G, et al. Ultrasound-guided vacuum-
assisted core breast biopsy: experience with 406 cases. Breast
Cancer Res Treat 2007;102:103–10.
21. Schueller G, Schueller-Weidekamm C, Helbich TH. Accuracy
of ultrasound-guided, large-core needle breast biopsy. Eur
Radiol 2008;18:1761–73.
DCIS underestimation rate for ultrasound-guided ACNB vs VAB
The British Journal of Radiology, August 2012 e355
22. Smith DN, Rosenfield Darling ML, Meyer JE, Denison CM,
Rose DI, Lester S, et al. The utility of ultrasonographically
guided large-core needle biopsy: results from 500 consecu-
tive breast biopsies. J Ultrasound Med 2001;20:43–9.
23. Youk JH, Kim E-K, Kim MJK, Oh KK. Sonographically
guided 14-gauge core needle biopsy of breast masses: a
review of 2,420 cases with long-term follow-up. AJR Am J
Roentgenol 2008;190:202–7.
24. Han B, Choe Y, Ko Y, Nam S, Kim J, Yang J. Stereotactic core-
needle biopsy of non-mass calcifications: outcome and accuracy
at long-term follow-up. Korean J Radiol 2003;4:217–23.
25. Schueller G, Jaromi S, Ponhold L, Fuchsjaeger M,
Memarsadeghi M, Rudas M, et al. US-guided 14-gauge
core-needle breast biopsy: results of a validation study in
1352 cases. Radiology 2008;248:406–13.
26. Pinder SE. Ductal carcinoma in situ (DCIS): pathological
features, differential diagnosis, prognostic factors and
specimen evaluation. Mod Pathol 2010;23:S8–13.
27. KimMJ, Kim E-K, Kwak JY, Son EJ, Park B-W, Kim S-I, et al.
Nonmalignant papillary lesions of the breast at US-guided
directional vacuum-assisted removal: a preliminary report.
Eur Radiol 2008;18:1774–83.
28. Liberman L, Drotman M, Morris E, LaTrenta L, Abramson
A, Zakowski M, et al. Imaging-histologic discordance at
percutaneous breast biopsy. Cancer 2000;89:2538–46.
29. Liberman L, Smolkin J, Dershaw DD, Morris E, Abramson A,
Rosen P. Calcification retrieval at stereotactic, 11-gauge, direc-
tional, vacuum-assisted breast biopsy. Radiology 1998;208:251–60.
30. Soo M, Baker J, Rosen E, Vo T. Sonographically guided
biopsy of suspicious microcalcifications of the breast: a pilot
study. AJR Am J Roentgenol 2002;178:1007–15.
31. Parker S, Klanus A. Performing a breast biopsy with a
directional, vacuum-assisted biopsy instrument. Radiographics
1997;17:1233–52.
32. Ikeda DM, Andersson I. Ductal carcinoma in situ: atypical
mammographic appearances. Radiology 1989;172:661–6.
33. Dershaw DD, Abramson A, Kinne DW. Ductal carcinoma in
situ: mammographic findings and clinical implications.
Radiology 1989;170:411–15.
34. Schoonjans JM, Brem RF. Fourteen-gauge ultrasonographi-
cally guided large-core needle biopsy of breast masses.
J Ultrasound Med 2001;20:967–72.
35. Crowe JP Jr, Patrick RJ, Rybicki LA, Grundfest SF, Kim JA,
Lee KB, et al. Does ultrasound core breast biopsy predict
histologic finding on excisional biopsy? Am J Surg 2003;
186:397–9.
36. Sauer G, Deissler H, Strunz K, Helms G, Remme E, Koretz
K, et al. Ultrasound-guided large-core needle biopsies of
breast lesions: analysis of 962 cases to determine the
number of samples for reliable tumour classification. Br J
Cancer 2005;92:231–5.
37. Crystal P, Koretz M, Shcharynsky S, Makarov V, Strano S.
Accuracy of sonographically guided 14-gauge core-needle
biopsy: results of 715 consecutive breast biopsies with at least
two-year follow-up of benign lesions. J Clin Ultrasound
2005;33:47–52.
Y J Suh, M J Kim, E-K Kim et al
e356 The British Journal of Radiology, August 2012
